{
    "clinical_study": {
        "@rank": "136185", 
        "arm_group": [
            {
                "arm_group_label": "15% CLINISOL 0.04 g/kg/hr", 
                "arm_group_type": "Experimental", 
                "description": "15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection."
            }, 
            {
                "arm_group_label": "15% CLINISOL 0.08 g/kg/hr", 
                "arm_group_type": "Experimental", 
                "description": "15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection."
            }, 
            {
                "arm_group_label": "15% CLINISOL 0.13 g/kg/hr", 
                "arm_group_type": "Experimental", 
                "description": "15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the best rate of infusion of amino acids (15%\n      CLINISOL - sulfite-free (Amino Acid) Injection) for nutrition in subjects with with stages\n      II to IVB head and neck cancer."
        }, 
        "brief_title": "Dosing Study of Amino Acids in Seriously Ill Patients", 
        "condition": "Parenteral Nutrition (No Primary Condition Studied)", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have Stages II to IVB head and neck cancer receiving radiation and may also be\n             receiving chemotherapy.\n\n             * Subjects are eligible for inclusion in the study regardless of primary Stages II to\n             IVB head and neck cancer treatment modality (eg, surgery, chemotherapy).\n\n          -  Have voluntarily signed and dated a written informed consent form (ICF) after the\n             nature of the study was explained to them.\n\n          -  Female subjects must be of non childbearing potential (defined as postmenopausal for\n             at least 1 year or surgically sterile [bilateral tubal ligation, bilateral\n             oophorectomy or hysterectomy]) or;\n\n          -  Female subjects of childbearing potential must be using adequate contraception\n             (practicing 1 of the following methods of birth control):\n\n               -  total abstinence from sexual intercourse (minimum of 1 complete menstrual cycle\n                  before study entry),\n\n               -  a vasectomized partner,\n\n               -  contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior\n                  to study drug administration,\n\n               -  intrauterine device (IUD), or\n\n               -  double barrier method (condoms, sponge, diaphragm, or vaginal ring with\n                  spermicidal jellies or cream).\n\n          -  Female subjects must have a negative serum or urinary pregnancy test result at\n             screening (serum specimen must be obtained within 14 days prior to baseline).\n\n        Exclusion Criteria:\n\n          -  Had a loss of > 10% of body weight within the 3 month period prior to the study as\n             noted in the subjects medical history chart.\n\n          -  Have renal disease as determined by an estimated glomerular filtration rate (eGFR) <\n             30 mL/min/1.73m2.\n\n          -  Have a hemoglobin level of < 9 g/dl.\n\n          -  Have Stage 0, I, or IVC metastatic cancer.\n\n          -  Have diabetes.\n\n          -  Have any reason which, in the opinion of the Investigator, would prevent the subject\n             from safely participating in the study.\n\n          -  Have, in the opinion of the Investigator, a dependence on alcohol.\n\n          -  Have, in the opinion of the Investigator, a dependence on illicit drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923480", 
            "org_study_id": "CT-12-0012"
        }, 
        "intervention": [
            {
                "arm_group_label": "15% CLINISOL 0.04 g/kg/hr", 
                "intervention_name": "15% CLINISOL - Sulfite-free (Amino Acid) Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "15% CLINISOL 0.08 g/kg/hr", 
                "intervention_name": "15% CLINISOL - Sulfite-free (Amino Acid) Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "15% CLINISOL 0.13 g/kg/hr", 
                "intervention_name": "15% CLINISOL - Sulfite-free (Amino Acid) Injection", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72205"
                }, 
                "name": "University of Arkansas for Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Determination of the Optimal Infusion Rate of Amino Acids in Seriously Ill Patients", 
        "overall_contact": {
            "last_name": "Baxter Healthcare Corporation", 
            "phone": "1-800-422-9837"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in net protein synthesis", 
            "safety_issue": "No", 
            "time_frame": "Twelve times during each 7 hour visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923480"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "Five times during each 7 hour visit"
            }, 
            {
                "measure": "Plasma concentration of 19 amino acids", 
                "safety_issue": "No", 
                "time_frame": "Three times during each 7 hour visit"
            }, 
            {
                "measure": "Plasma stable isotope enrichment of phenylalanine and tyrosine", 
                "safety_issue": "No", 
                "time_frame": "Twelve times during each 7 hour visit"
            }, 
            {
                "measure": "Plasma concentration of glucose", 
                "safety_issue": "No", 
                "time_frame": "Nine times during each 7 hour visit"
            }, 
            {
                "measure": "Serum concentration of insulin", 
                "safety_issue": "No", 
                "time_frame": "Five times during each 7 hour visit"
            }
        ], 
        "source": "Baxter Healthcare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baxter Healthcare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}